VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 82.9% in January

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 112,300 shares, an increase of 82.9% from the December 31st total of 61,400 shares. Based on an average trading volume of 118,200 shares, the short-interest ratio is presently 1.0 days. Approximately 0.9% of the company’s stock are sold short.

Insider Activity

In other news, Director Patrick G. Lepore bought 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $2.92 per share, for a total transaction of $43,800.00. Following the completion of the purchase, the director now owns 51,472 shares of the company’s stock, valued at approximately $150,298.24. This represents a 41.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

VYNE has been the subject of several research reports. BTIG Research initiated coverage on VYNE Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $8.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $5.75 price objective on shares of VYNE Therapeutics in a research note on Tuesday, January 14th.

VYNE Therapeutics Stock Performance

Shares of VYNE stock opened at $2.36 on Friday. VYNE Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $4.30. The business has a fifty day simple moving average of $2.92 and a 200-day simple moving average of $2.41.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. On average, sell-side analysts expect that VYNE Therapeutics will post -0.97 EPS for the current year.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.